Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

NCT06141226 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

148

Enrollment

OTHER

Sponsor class

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG: TQB2450 +Anlotinib+Docetaxel
DRUG: TQB2450 +Androtinib Placebo+Docetaxel

Sponsor

Tianjin Medical University Cancer Institute and Hospital